

**ASX RELEASE**

**17 September 2019**

**Section 708A Notice – Allotment of 1,700,000 Shares**

Amplia Therapeutics Limited (“ATX” or “the Company”) has today effected an allotment of 1,700,000 ordinary fully paid shares at the issue price of \$0.10 per share (with 850,000 Options attaching on a 1 for 2 basis) to raise gross proceeds of \$170,000 for preclinical studies relating to the Company’s drug candidate AMP945 as well as providing the Company with additional working capital.

All of the shares issued will rank pari passu with existing ATX ordinary shares.

In accordance with Section 708A (5)(e) of the Act, the Company gives notice that:

- The Company has issued these shares without disclosure to investors under Part 6D.2 of the Act;
- As at the date of this notice, the Company has complied with:
  - the provisions of Chapter 2M of the Act as they apply to the Company;
  - Section 674 of the Act
- As at the date of this notice there is no excluded information (as defined in Sections 708A (7) and 708A(8) of the Act) which is required to be disclosed by the Company under Section 708(6) of the Act.

- End -

**For Further Information**

Andrew J. Cooke  
Director and Company Secretary  
[andrew@ampliatx.com](mailto:andrew@ampliatx.com)  
[www.ampliatx.com](http://www.ampliatx.com)